Published in Cancer Biol Ther on April 01, 2010
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol (2015) 1.85
Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res (2011) 1.78
MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res (2011) 1.59
MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther (2011) 1.58
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol (2011) 1.53
Wee1 kinase as a target for cancer therapy. Cell Cycle (2013) 1.22
Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther (2013) 1.13
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res (2012) 1.11
Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia (2012) 1.09
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int (2012) 1.06
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res (2014) 1.05
Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res (2014) 1.03
Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One (2013) 1.03
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia (2014) 0.97
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res (2015) 0.95
Targeting the Checkpoint to Kill Cancer Cells. Biomolecules (2015) 0.94
Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther (2010) 0.93
Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol (2013) 0.93
Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther (2014) 0.91
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res (2011) 0.91
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle (2012) 0.90
CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol (2014) 0.90
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol (2014) 0.89
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. J Exp Clin Cancer Res (2016) 0.89
Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer (2014) 0.88
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res (2015) 0.86
Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther (2014) 0.86
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer (2015) 0.84
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia (2014) 0.83
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett (2014) 0.82
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer (2017) 0.81
WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet (2013) 0.80
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia (2015) 0.80
Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther (2016) 0.79
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Mol Cancer Ther (2016) 0.79
Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget (2016) 0.78
A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity. Proc Natl Acad Sci U S A (2015) 0.78
Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biol Ther (2015) 0.78
Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins. Clin Cancer Res (2015) 0.77
A small molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther (2017) 0.76
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget (2016) 0.76
The cell cycle checkpoint inhibitors in the treatment of leukemias. J Hematol Oncol (2017) 0.75
WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Sci Rep (2016) 0.75
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death Differ (2016) 0.75
Cytokinetic effects of Wee1 disruption in pancreatic cancer. Cell Cycle (2016) 0.75
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. Proc Natl Acad Sci U S A (2017) 0.75
Not so WEE: targeting G₂/M to kill mesothelioma cells. Cancer Biol Ther (2014) 0.75
Sustaining the spindle assembly checkpoint to improve cancer therapy. Mol Cell Oncol (2015) 0.75
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Oncotarget (2016) 0.75
WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett (2017) 0.75
Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol (2017) 0.75
Dual targeting of WEE1 and PLK1 by AZD1775 elicits single agent cellular anticancer activity. ACS Chem Biol (2017) 0.75
Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer. Oncol Lett (2017) 0.75
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol (2006) 4.07
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther (2009) 2.50
Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem (2003) 2.36
Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity (2004) 2.29
CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol (2004) 2.25
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol (2004) 1.91
Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med (2004) 1.59
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer (2004) 1.52
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther (2010) 1.48
Pivotal advance: glycyrrhizin restores the impaired production of beta-defensins in tissues surrounding the burn area and improves the resistance of burn mice to Pseudomonas aeruginosa wound infection. J Leukoc Biol (2009) 1.46
Cryptococcal encephalitis in thermally injured mice is accelerated by type 2 T-cell responses. Crit Care Med (2002) 1.39
Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res (2006) 1.32
A protein associated with toll-like receptor 4 (PRAT4A) regulates cell surface expression of TLR4. J Immunol (2006) 1.21
Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. J Biol Chem (2009) 1.17
Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol (2003) 1.13
Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer (2009) 1.11
Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Curr Top Med Chem (2005) 1.09
Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells. Kidney Int (2003) 1.04
Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. Protein Sci (2007) 1.01
Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem (2006) 1.01
Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology (2009) 0.99
Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis. J Biol Chem (2005) 0.98
A molecule that is associated with Toll-like receptor 4 and regulates its cell surface expression. Biochem Biophys Res Commun (2005) 0.97
Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci U S A (2006) 0.95
An essential role of macrophage inflammatory protein 1alpha/CCL3 on the expression of host's innate immunities against infectious complications. J Leukoc Biol (2002) 0.94
Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest (2002) 0.94
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res (2009) 0.91
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics (2008) 0.91
Preparation and characterization of new chiral nitronyl nitroxides bearing a stereogenic center in the imidazolyl framework. J Org Chem (2004) 0.90
Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther (2007) 0.90
Cooperative role of macrophages and neutrophils in host Antiprotozoan resistance in mice acutely infected with Cryptosporidium parvum. Infect Immun (2008) 0.90
Role of polymorphonuclear neutrophils on infectious complications stemming from Enterococcus faecalis oral infection in thermally injured mice. J Immunol (2008) 0.89
Enterococcus faecalis translocation in mice with severe burn injury: a pathogenic role of CCL2 and alternatively activated macrophages (M2aMphi and M2cMphi). J Leukoc Biol (2009) 0.89
Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding. Acta Crystallogr D Biol Crystallogr (2010) 0.89
Effectiveness of the timing principle with high-dose rocuronium during rapid sequence induction with lidocaine, remifentanil and propofol. J Anesth (2010) 0.89
Marginal zone B-cell lymphoma of minor salivary gland representing tumor-forming amyloidosis of the oral cavity. A case report. J Oral Pathol Med (2006) 0.89
Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med (2008) 0.88
Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines. Mol Cancer (2009) 0.88
Lack of Th17 cell generation in patients with severe burn injuries. J Immunol (2011) 0.87
Glycyrrhizin inhibits R5 HIV replication in peripheral blood monocytes treated with 1-methyladenosine. Pathobiology (2005) 0.87
The distal sequence element of the selenocysteine tRNA gene is a tissue-dependent enhancer essential for mouse embryogenesis. Mol Cell Biol (2005) 0.87
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines. Mol Cancer Ther (2009) 0.87
Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions. Cytokine (2006) 0.87
Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics (2009) 0.87
Carcinogenicity of dimethylarsinic acid in Ogg1-deficient mice. Cancer Sci (2007) 0.86
Soluble IL-4 receptor improves the skin-graft-associated cytomegalovirus infection in thermally injured mice. Burns (2003) 0.86
CCL2, a product of mice early after systemic inflammatory response syndrome (SIRS), induces alternatively activated macrophages capable of impairing antibacterial resistance of SIRS mice. J Leukoc Biol (2004) 0.86
Flexible metallic ultrasonic transducers for structural health monitoring of pipes at high temperatures. IEEE Trans Ultrason Ferroelectr Freq Control (2010) 0.86
CCL1 released from M2b macrophages is essentially required for the maintenance of their properties. J Leukoc Biol (2012) 0.86
Appearance of monocyte chemoattractant protein 1 (MCP-1) early after thermal injury: role in the subsequent development of burn-associated type 2 T-cell responses. Ann Surg (2002) 0.86
Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Bioorg Med Chem Lett (2009) 0.84
Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients. Pathobiology (2003) 0.84
Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist. Br J Pharmacol (2002) 0.83
Pathogenic role of macrophages in intradermal infection of methicillin-resistant Staphylococcus aureus in thermally injured mice. Infect Immun (2010) 0.83
Increased norepinephrine production associated with burn injuries results in CCL2 production and type 2 T cell generation. Burns (2004) 0.83
Similarity and difference in the acute lung injury induced by a radiographic contrast medium and an anticancer agent paclitaxel in rats. Toxicol Lett (2004) 0.83
Insulin-like growth factor-I/insulin-like growth factor binding protein-3 alters lymphocyte responsiveness following severe burn. J Surg Res (2004) 0.82
Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. Biochem Biophys Res Commun (2004) 0.82
Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples. Mol Cancer (2011) 0.82
Glycyrrhizin inhibits neutrophil-associated generation of alternatively activated macrophages. Cytokine (2006) 0.82
Contribution of the sympathetic nervous system on the burn-associated impairment of CCL3 production. Cytokine (2005) 0.82
Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology (2013) 0.82
Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum Genet (2010) 0.82
Sacral arachnoid cyst associated with marfan syndrome. Intern Med (2005) 0.81
Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci (2006) 0.80
[An autopsy case of amyotrophic lateral sclerosis with prominent muscle cramps, fasciculation, and high titer of anti-voltage gated potassium channel (VGKC) complex antibody]. Rinsho Shinkeigaku (2014) 0.80
Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics (2009) 0.80
Effect of CCL2 antisense oligodeoxynucleotides on bacterial translocation and subsequent sepsis in severely burned mice orally infected with Enterococcus faecalis. Eur J Immunol (2011) 0.80
A high-throughput phage display screening method using a combination of real-time PCR and affinity chromatography. Comb Chem High Throughput Screen (2006) 0.79
Visualization of the azygos arch valves on multidetector-row computed tomography. Heart Vessels (2008) 0.78
Impairment of the host's antibacterial resistance by norepinephrine activated neutrophils. Burns (2007) 0.78
Cloning and characterization of the rhesus monkey nociceptin/orphanin FQ receptor. Genes Genet Syst (2009) 0.78
CCL2 as a trigger of manifestations of compensatory anti-inflammatory response syndrome in mice with severe systemic inflammatory response syndrome. J Leukoc Biol (2006) 0.78
[Crisis management during regional anesthesia including peripheral nerve block, epidural anesthesia and spinal anesthesia]. Masui (2009) 0.78
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs (2010) 0.78